Companies · Biotech
Boulder · CO, USA · Biotech · founded 2025 · http://playhealth.com
Diligence memoA one-page analyst read on Play Health — recommendation, valuation, rhythm, risks.→Play Health: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Play Health is one of 233 Biotech companies tracked from Boulder, CO, USA, on record since 2025. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Perimenopause Care Platform
Play Health is building a perimenopause care platform to provide women and their providers with the tools they need to relieve symptoms fast. It is led by technical, second-time, YC-backed founders Andrea Mazzocchi, PhD and Ian Miller, with an exit and a unicorn between them. Over 30 million women in the U.S. are experiencing perimenopause symptoms, spending an estimated $15B+ annually on symptom management. Despite this most only receive generic solutions and struggle to find effective symptom relief. We're bringing evidence-based perimenopause care to women through partnerships with medical practices and employer and health benefits programs. Our platform integrates personalized symptom, medication, and lifestyle data to generate AI-powered insights and clinical protocols, enabling providers to deliver specialized care. Every clinical interaction enriches our longitudinal dataset allowing us to create better outcomes for patients, deeper insights for providers, and expand into women’s health broadly. This also enables us to partner with pharma and biotech companies developing therapeutics and diagnostics for women's health.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Play Health is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x Science | Biotech | — | — | — | same sector |
| 1849 bio | Biotech | — | — | — | same sector |
| 1910 | Biotech | — | — | — | same sector |
| 20n | Biotech | — | — | — | same sector |
| 54Gene, Inc. | Biotech | Series B | $48.3M | $599.1M | same sector |
| Abacus Bioscience Inc. | Biotech | Series A | $4.4M | $46.6M | same sector |
| Abalone Bio | Biotech | — | — | — | same sector |
| Acoustic Wave Cell Therapy, Inc. | Biotech | Series A | $20.5M | $85.0M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| LunaJoy Health AI-powered scalable infrastructure + mental health services, starting… | Healthtech | — | — | 77% |
| Play-it Health, Inc. | Healthtech | Seed | $28.3M | 77% |
| Rejuvenation Technologies Inc. mRNA therapeutics to extend healthspan entering clinical trials | Pharma | — | — | 76% |
| Veera Health We treat women with Polycystic Ovary Syndrome in India | Healthtech | — | — | 76% |
| Circle Medical Modern primary care via video and in-person | Healthtech | — | — | 75% |
| Synapticure, Inc. We deliver personalized medicine for neurodegenerative patients | Biotech | Series C | $332.9M | 75% |
| Health Platforms, Inc. | Healthtech | Series A | $112.9M | 74% |
| Hormone Health Inc. | Healthtech | Pre-Seed | $21.5M | 74% |
See where Play Health sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Play Health, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.